Lyme Disease Research at University of Guelph Reaches Pivotal Milestone: A Biosensor for Home Testing
A groundbreaking collaboration between the University of Guelph (U of G) and Ben Gurion University of the Negev in Israel has led to the development of a biosensor that could revolutionize Lyme disease detection. This innovative technology, created by the G. Magnotta Research Lab, has the potential to make Lyme disease testing more accessible and efficient, offering a new approach to diagnosing this tick-vectored bacterial infection.
The biosensor, led by Dr. Melanie Wills and Dr. Vladimir Bamm, translates the presence of a Lyme disease biomarker in a blood sample into an electrical signal, which can be read by a computer. This simple yet powerful tool could enable individuals to test for Lyme disease at home, similar to how people with diabetes use a glucometer.
The sensor's integrated circuit, a microchip, can detect even the smallest amounts of the Lyme disease biomarker, making it a highly sensitive and specific method of detection. This is a significant improvement over the current two-tier testing approach used in Canada, which is not sensitive enough in the early stages of infection and relies on the immune response rather than the pathogen itself.
Lyme disease is a growing concern globally, with rising human cases and increasing tick populations due to climate change. The number of people contracting Lyme disease in Canada is rising by approximately 20% annually, with the highest cases reported in Nova Scotia, Ontario, and Quebec. However, the actual number of infections is believed to be higher than reported, as the current testing methods have limitations.
The G. Magnotta Research Lab's collaboration with Dr. Gil Shalev from Ben Gurion University has been instrumental in making this breakthrough. By merging electrical engineering, biochemistry, biophysics, physics, material science, microbiology, and medical sciences, the team has created a feasible solution. Dr. Bamm emphasizes the importance of this interdisciplinary approach, stating, 'For us, it is important to use all components of blood, eliminating the risk of disposing of blood that could have the identifiable pathogen.'
While the biosensor is currently a lab prototype, the team is optimistic about its potential. Dr. Wills states, 'We have the engine; now we need to build the car.' The next steps include clinical testing, miniaturization, mass production, and productization to make the biosensor viable for market. This research is supported by the G. Magnotta Foundation, a non-profit organization dedicated to advancing Lyme disease research through scientific investigation.
The development of this biosensor is a significant milestone in Lyme disease research, offering a more efficient and accessible testing method. As the team continues to refine and develop the technology, the potential for a more effective and widespread approach to Lyme disease diagnosis becomes a reality.
